Lv2
116 积分 2021-11-15 加入
Korea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different?
2小时前
已完结
第7版日本胃癌治疗指南更新要点
2小时前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
10天前
已完结
原发性骨质疏松症诊疗指南 (2017)
11天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
26天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
26天前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
26天前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
26天前
已完结
皖公网安备34019202002308
